Jurisdiction Twist Supercharges FCA War

The Fifth Circuit’s en banc dismissal of Planned Parenthood’s interlocutory appeal did not end the case; it cleared the runway for a high-stakes False Claims Act fight in district court over whether Texas Medicaid dollars were improperly billed and retained.

The Short Version

The full Fifth Circuit dismissed Planned Parenthood’s interlocutory appeal for lack of jurisdiction, leaving a $1.8 billion False Claims Act case to proceed in district court.
Texas and an anonymous relator allege Planned Parenthood affiliates continued billing Medicaid after termination announcements and failed to repay funds once terminations took effect.
The district court previously declined to end the case on immunity grounds, keeping Planned Parenthood and affiliates in the litigation posture to face trial-level proceedings.
Prior billing disputes show compliance risks exist in Medicaid, though converting them into large-scale FCA liability is demanding and fact-intensive.

What the Fifth Circuit actually did—and why it matters

The Fifth Circuit sitting en banc dismissed Planned Parenthood’s interlocutory appeal in the Texas Medicaid fraud suit, squarely on jurisdictional grounds. That move did not bless or reject the fraud theory; it returned the case to the Amarillo federal trial court, where the claims and defenses will be proved or defeated the old-fashioned way—through discovery, expert analysis, and, if necessary, trial. The opinion’s bottom line is concise: the court lacked jurisdiction to take up the interim appeal and therefore dismissed it, which means the whistleblowers’ and Texas’s False Claims Act (FCA) case remains live in the district court.

Understanding the appellate posture is critical. An interlocutory appeal is an attempt to seek appellate review before a final judgment. The Fifth Circuit’s refusal to entertain that appeal keeps the merits on the trial judge’s docket; it is not a ruling that fraud did or did not occur. Practically, however, it is a significant inflection point: the plaintiffs keep leverage, discovery momentum can resume, and any dispositive rulings will now come from the district court unless and until a proper appeal lies.

The allegations: post-termination billing and non-repayment

The core theory is straightforward to state and complex to prove. According to public descriptions of the suit, Texas and an anonymous relator contend that Planned Parenthood affiliates continued to bill—and collect—Medicaid payments after state authorities initiated actions to end the affiliates’ participation, and that affiliates failed to return funds once those terminations became effective. In FCA terms, that frames two species of liability: presenting false claims and “reverse” false claims (improper retention of money owed to the government). Reuters summarized the complaint along those lines, highlighting continued billing after termination announcements and non-reimbursement after terminations took effect.

Texas is not on the sidelines. The state joined the case, aligning itself with the relator’s theory and seeking treble damages and penalties consistent with FCA remedies. Planned Parenthood Texas affiliates’ own public statement acknowledges that “The state of Texas and an anonymous plaintiff are suing Planned Parenthood for more than $1.8 billion,” situating the litigation as an existential financial threat within the Texas network. That dollar figure, which far exceeds the underlying reimbursements, reflects the FCA’s multiplier and per-claim penalties architecture rather than the raw size of the challenged payments.

Procedural history: from immunity fights to a live merits case

The district court previously declined to short-circuit the case on immunity and related threshold grounds, leaving Planned Parenthood to face trial-level proceedings alongside its affiliates. Coverage at the time noted Judge Matthew Kacsmaryk’s rulings that kept the case moving; the subsequent appeal targeted the posture of attorney-immunity and similar defenses, which the Fifth Circuit, sitting en banc, ultimately declined to review midstream for jurisdictional reasons. The result is a litigation channel that points back to the trial court for the hard questions: What exactly was billed, when, under which provider identifiers, relative to which termination effective dates—and with what advice or justification in place at the time?

That is where FCA cases are won or lost. Terminology matters: a “termination announcement” is not necessarily a termination “effective date,” and injunctions or administrative appeals can create windows where billing is lawful pending resolution. The plaintiffs say the line was crossed anyway; Planned Parenthood says no court has found fraud and argues it acted within the rules. The Fifth Circuit’s jurisdictional dismissal leaves those competing narratives to be tested on a factual record.

How FCA liability would be established in a Medicaid-billing dispute

The FCA requires more than negligence; it demands falsity that is material to payment and a culpable mental state—knowledge, which includes reckless disregard. In a Medicaid setting, the mechanism turns on provider eligibility, claim content (CPT/HCPCS codes, modifiers), and the timing interplay among enrollment status, state directives, and any judicial or administrative stays. If the state’s termination became effective on a date certain, and if no stay or continued-eligibility mechanism was operative, then claims paid thereafter could be “ineligible” by definition; if funds were received after eligibility lapsed, prompt refund obligations can attach, with failure to return creating reverse-FCA exposure.

To prove that at scale, plaintiffs must marshal claim-by-claim data: adjudication logs, remittance advices, provider numbers, dates of service versus dates of payment, and the documentary chain showing when termination became effective. Internal emails and counsel memoranda matter because they bear on scienter—what decision-makers understood and intended when claims went out or repayments did not.

What prior cases do—and do not—tell us

Two threads of prior litigation provide context. First, not every billing-compliance dispute becomes fraud. The Eighth Circuit rejected a former director’s broad fraud theory against a Planned Parenthood affiliate in Iowa, concluding the evidence didn’t establish deliberate misclassification to defraud Medicaid; that outcome underscores how demanding the FCA’s proof burdens are and cautions against assuming that recurring billing issues always equal fraud. Second, enforcement history shows that compliance lapses can and do occur. The HHS Office of Inspector General announced a $1.5 million resolution with a Planned Parenthood entity over claims billed under the wrong provider number and services by non-enrolled practitioners across several states—classic administrative-compliance failures that, while serious, are typically resolved short of treble-damages warfare.

These two data points pull in different directions but ultimately reinforce the same operational lesson: facts rule. The existence of past errors elsewhere neither proves nor disproves the Texas allegations; a loss in a different circuit on a different record does not forecast defeat in this one. The Texas case will turn on its own evidence and the specific legal status of affiliates at specific times relative to the payments at issue.

Where the real disagreements lie now

With appellate detours off the board for the moment, the genuine disagreements are granular. They include: the precise effective dates of Medicaid terminations for each affiliate; whether any injunctions or administrative processes permitted interim billing; whether affiliates submitted new claims post-effective date or merely received payments on pre-termination services; what repayment obligations attached when, and how quickly affiliates acted; and, critically, whether internal legal guidance and decision logs support or undercut a finding of knowing submission or retention in violation of federal and state law. Disputes over the national entity’s liability theory—corporate control, agency, and participation—also remain, given PPFA’s position that it cannot be sued on this record.

On damages, expect sharp fights over materiality and multiplier math. Even if liability attaches to a subset of payments, defendants will argue that the government’s own conduct—continued processing, communications, or ambiguity in status—cuts materiality and curbs penalties. Plaintiffs will press the opposite: that provider ineligibility is quintessentially material and that reverse-FCA penalties apply where timely refunds did not occur.

What to watch next: evidence, not rhetoric

The next meaningful developments will be in the district court docket: discovery orders, summary-judgment briefing built on claim-level exhibits, and any expert reports sorting allowable from non-allowable claims by date and status. If the case clears summary judgment, a trial would tee up credibility and scienter determinations that appellate courts are loath to second-guess. For observers, the signal-to-noise test is simple. Look for the documents that match termination effective dates to claims and payments, and for contemporaneous internal guidance explaining why billing continued or why repayments were delayed. Those exhibits decide FCA cases; press releases do not.